Magle Group swaps $13M in debt and loans for equity to fix its balance sheet
What's the deal? Magle Chemoswed Holding ABDealroom has a profile for this one. Try Dealroom →, a Swedish pharmaceutical group, has completed a set-off share issue and three directed share issues worth US$15.1M, converting bond and loan claims into equity. The board resolved the issues on September 10, 2026, following approval at an extraordinary general meeting on August 26.
Why now? The move caps a restructuring of the company's debt and capital structure announced on July 10, 2026. A written procedure with bondholders, initiated by Nordic Trustee & Agency ABDealroom has a profile for this one. Try Dealroom →, completed successfully on July 30 and paved the way for the conversions.
What's the endgame? The set-off issue turned 74,254,853 new shares over to bondholders at US$0.12 per share, covering a debt-for-equity swap plus upfront, underwriting, and consent fees. Separately, three directed issues allotted shares to investors and board members, largely by setting off outstanding claims.
Who took part? PRS1 ApS and MB Holding Køge ApSDealroom has a profile for this one. Try Dealroom → anchored the directed issues, with a combined US$3.84M settled against subordinated loans, plus a further US$906.6K from PRS1 ApS alone. Current and former board members took US$1.37M in shares, of which US$24.2K was paid by set-off.
The signal: Debt-for-equity swaps hand creditors ownership in exchange for wiping claims off the books — a lifeline for balance sheets, but one that dilutes existing shareholders. For Magle Group, the swap marks a step up from its prior financing and a reset of its capital structure after mounting bond obligations.
Read more: placera.se
Image credit: foteih
